Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    Ruby Khatun Khatun
    Ruby Khatun Khatun
      • Home
      • Ruby Khatun Khatun

      Articles By : Ruby Khatun Khatun

      Merck

      Merck's Keytruda fails pivotal gastric cancer trial

      Ruby Khatun Khatun17 Dec 2017 9:45 AM IST
      Merck & Co Inc said on Thursday a key late-stage trial testing its blockbuster drug, Keytruda, failed to meet its main goal of extending lives of...
      Merck to make new bid to enter US multiple sclerosis pill market

      Merck to make new bid to enter US multiple sclerosis pill market

      Ruby Khatun Khatun17 Dec 2017 9:30 AM IST
      FRANKFURT: Germany’s Merck KGaA is reviving plans to bring an oral multiple sclerosis (MS) treatment to the U.S. market, hoping for blockbuster sales...
      1700 percent on items charged by Fortis Memorial Research Institute, says NPPA

      1700 percent on items charged by Fortis Memorial Research Institute, says NPPA

      Ruby Khatun Khatun16 Dec 2017 4:47 PM IST
      Gurugram: Fortis hospital at Gurugram charged as high as 1700 percent cent margin on consumables and medicines used for the treatment of a dengue...
      Torrent completes acquisition of branded business of Unichem Labs

      Torrent completes acquisition of branded business of Unichem Labs

      Ruby Khatun Khatun16 Dec 2017 3:58 PM IST
      New Delhi: Torrent Pharmaceuticals said it has completed the Rs 3,600 crore acquisition of Unichem's branded business for India and Nepal.The...
      SC refers 344 fixed dose combination medicines to Drug Advisory Board for Re-examination

      SC refers 344 fixed dose combination medicines to Drug Advisory Board for Re-examination

      Ruby Khatun Khatun16 Dec 2017 3:40 PM IST
      New Delhi: The Supreme Court referred 344 fixed dose combination (FDC) medicines, including well- known brands like Corex cough syrup, Vicks Action...
      Sanofi India appoints N Rajaram as managing director

      Sanofi India appoints N Rajaram as managing director

      Ruby Khatun Khatun16 Dec 2017 11:50 AM IST
      New Delhi: Pharma company Sanofi India said it has elevated N Rajaram as the managing director of the company with effect from January 1, 2018.Rajaram...
      MTaI  response to knee implant price control

      MTaI response to knee implant price control

      Ruby Khatun Khatun16 Dec 2017 10:30 AM IST
      New Delhi: Patient access is an indisputable goal. The ways governments try to reach it are many. The easier methods are usually unfruitful. A deeper...
      Singapore institutes collaborate with Samsung Medical Center to improve treatment of liver cancer

      Singapore institutes collaborate with Samsung Medical Center to improve treatment of liver cancer

      Ruby Khatun Khatun16 Dec 2017 10:15 AM IST
      SINGAPORE: Scientists and doctors from Singapore institutes are collaborating with Samsung Medical Center (SMC), a leading academic medical center in...
      FDA proposes new fast path to market for certain medical devices

      FDA proposes new fast path to market for certain medical devices

      Ruby Khatun Khatun16 Dec 2017 10:00 AM IST
      The U.S. Food and Drug Administration on Monday proposed creating a new fast track to market for certain medical devices and a potential reduction in...
      Bumper crop of new drugs fails to lift big pharma Research and Development returns

      Bumper crop of new drugs fails to lift big pharma Research and Development returns

      Ruby Khatun Khatun16 Dec 2017 9:45 AM IST
      LONDON: It is shaping up to be a bumper year for drug approvals, with U.S. officials clearing twice as many novel medicines as in 2016, yet returns on...
      Sanofi pins hopes on new drugs after setbacks

      Sanofi pins hopes on new drugs after setbacks

      Ruby Khatun Khatun16 Dec 2017 9:30 AM IST
      PARIS: Sanofi’s promising pipeline of experimental drugs can help it overcome setbacks including the low uptake of a new cholesterol treatment and...
      4 Pharma Giants face price fixing allegations on Vidagliptin: CCI starts probe

      4 Pharma Giants face price fixing allegations on Vidagliptin: CCI starts probe

      Ruby Khatun Khatun15 Dec 2017 5:15 PM IST
      Mumbai: Trouble is mounting for 4 big pharma companies over price fixing of an anti-diabetic drug. An investigation has initiated on drug makers...
      PrevNext

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok